Terminated × Lymphoma, B-Cell, Marginal Zone × Clear all Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Phase 1 Terminated
18 enrolled
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
Phase 1 Terminated
84 enrolled
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
Phase 2 Terminated
18 enrolled 11 charts
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
Phase 2 Terminated
22 enrolled 20 charts
ELiPSE-1
Phase 1 Terminated
28 enrolled
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
Phase 2 Terminated
9 enrolled 12 charts
LYMFOR
Phase 3 Terminated
13 enrolled
GLEAN-1
Phase 1 Terminated
34 enrolled
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
Phase 2 Terminated
2 enrolled 6 charts
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Phase 1 Terminated
17 enrolled
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
Phase 2 Terminated
169 enrolled 10 charts
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Phase 3 Terminated
82 enrolled 11 charts
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Phase 1/2 Terminated
46 enrolled 35 charts
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Terminated
3 enrolled 11 charts
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Phase 1/2 Terminated
58 enrolled 11 charts
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 Terminated
21 enrolled
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 1/2 Terminated
97 enrolled
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
Phase 1/2 Terminated
8 enrolled
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Phase 1/2 Terminated
43 enrolled 15 charts
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Phase 1 Terminated
21 enrolled
Ipilimumab and Local Radiation for Selected Solid Tumors
Phase 1 Terminated
3 enrolled 5 charts
Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Phase 2 Terminated
5 enrolled
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Terminated
20 enrolled 8 charts
Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
Phase 2 Terminated
6 enrolled 7 charts
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
Phase 1 Terminated
97 enrolled
Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers
Phase 1 Terminated
5 enrolled
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Terminated
46 enrolled 18 charts
UNITY-NHL
Phase 2/3 Terminated
710 enrolled 2 FDA
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Phase 1 Terminated
10 enrolled
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Phase 1 Terminated
7 enrolled
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Phase 1/2 Terminated
20 enrolled 17 charts
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
Phase 1 Terminated
30 enrolled
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
Phase 3 Terminated
105 enrolled
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Phase 1 Terminated
2 enrolled 6 charts
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
Phase 1 Terminated
4 enrolled
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Phase 1 Terminated
5 enrolled
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
Phase 1/2 Terminated
39 enrolled
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Phase 2 Terminated
3 enrolled 17 charts
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
Phase NA Terminated
1 enrolled 3 charts
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase 1 Terminated
8 enrolled
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
Phase 2 Terminated
4 enrolled 12 charts
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
Phase NA Terminated
2 enrolled 11 charts
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Phase 1/2 Terminated
2 enrolled 4 charts
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Terminated
150 enrolled
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
Phase 2 Terminated
1 enrolled 4 charts
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
Phase NA Terminated
25 enrolled 15 charts
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
Yosemite
Phase 3 Terminated
295 enrolled 9 charts
Bridalveil
Phase 3 Terminated
475 enrolled 9 charts
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
Terminated
241 enrolled